Alignment Healthcare

Alignment Healthcare is the rare Medicare Advantage challenger that survived the brutal 2024-2025 reset in the sector. While UnitedHealth, Humana and Centene were taking margin hits from Medical Loss Ratio creep, MA Stars downgrades, and the 2025 CMS rate cut, John Kaos team kept membership growth above 30% and arrived at break-even adjusted EBITDA in 2025 — earlier than guidance suggested.

The differentiation versus the four big MA plans is the technology stack. AVA — Alignments proprietary care-orchestration platform — pulls real-time claims, clinical, and home-health data into a single risk-stratification engine. That allows Alignment to identify high-risk seniors before an ER visit happens, deploy in-home physician resources, and squeeze the gap between projected and actual Medical Loss Ratio. In 2025 the medical loss ratio came in at 87% — comfortably below the 89-91% peer median.

The 2026 question is whether membership growth can keep pace with the 35-40% trajectory without margin slippage. Alignment is expanding into Texas and Georgia for the 2027 plan year, and is one of the few MA plans rated 4.0 stars or better across all benchmark plans — a critical lever for both rebate dollars and member retention.

The most notable smart-money positioning in Alignment is Coatue Management, which has held a top-five position since the 2021 IPO at USD 18. Philippe Laffont sat through the 2022 collapse to USD 5, the 2024 recovery to USD 19, and now the 2026 consolidation around USD 15-16. Position size has stayed in the 5-7M share range across every quarter for three years — a textbook long-duration conviction signal.

The 2025 13Fs also show Foresite Capital and Mubadala Investment Company as new entrants. Foresite is a specialist healthcare growth fund with a strong track record on managed-care names. Mubadalas entry signals sovereign-wealth interest in US Medicare exposure as a long-duration aging-demographic theme.

Insider activity is mixed but interpretable. CEO John Kao sold 250,000 shares in February 2026 under a 10b5-1 plan dating from late 2024 — preplanned, not opportunistic. CFO Thomas Freeman has been a small periodic open-market buyer in the USD 50-100K range, consistent with personal accumulation rather than insider distribution.

Alignment trades at a forward P/E of approximately 22x on 2026 consensus EPS of USD 0.72, against the MA-plan median of 16x. The premium reflects the growth differential — Alignment is the only large MA plan with consensus 2027 revenue growth above 25%, versus low-single-digit growth at Humana and UnitedHealthcare. EV/Revenue at 0.95x is in line with the peer median of 0.85-1.05x, suggesting the market is paying for growth via the P/E multiple but not yet pricing in operating leverage. Street targets range from USD 14 (Wells Fargo, bear case assuming 2027 CMS rate cut) to USD 24 (Morgan Stanley, bull case at 4.5-Stars retention plus Texas success). The base case at USD 18-20 implies 15-25% upside from current levels.

1. June 2026: CMS Medicare Advantage 2027 rate notice — final rule typically released early April but quasi-final guidance lands in June via advance notice
2. October 2026: PY 2027 Star Ratings release from CMS — direct driver of 2028 rebate dollars and member retention
3. Q1 2027: Texas and Georgia MA plan market entry — first new-state expansion since 2022, key proof-point for replicability of AVA model

Alignment is one of the cleanest growth-versus-incumbent setups in healthcare. The MA sector is structurally attractive — aging US demographic, switching from traditional Medicare to MA still under 60% penetration — and the four big plans are managing for margin not membership growth. That leaves an open lane for any plan with a credible tech-enabled cost-management story plus 4-Star quality. AVA plus the Stars portfolio is exactly that. My main worry is CMS rate risk for 2028; this is a name where I would size in tranches around rate-notice calendar windows, not concentrate ahead of them. Current entry near USD 15-16 looks attractive for a 18-24 month hold targeting USD 22-24.